Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients
Background and aim Currently, a new oral diabetes medication comprises inhibition of the sodium-glucose co-transporter 2 (SGLT2), resulting in glycosuria, which may have a dislodging impact on stone ureter. The purpose of this trial was to examine and compare efficacy of empagliflozin in treatment o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Al-Azhar Assiut Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/azmj.azmj_53_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525272370741248 |
|---|---|
| author | Alsayed S. Abdelaziz Mohab AS. Abdalaziz Mostafa M. Ebraheem Ali A. Raheem Ayman M. Ghoneem |
| author_facet | Alsayed S. Abdelaziz Mohab AS. Abdalaziz Mostafa M. Ebraheem Ali A. Raheem Ayman M. Ghoneem |
| author_sort | Alsayed S. Abdelaziz |
| collection | DOAJ |
| description | Background and aim
Currently, a new oral diabetes medication comprises inhibition of the sodium-glucose co-transporter 2 (SGLT2), resulting in glycosuria, which may have a dislodging impact on stone ureter. The purpose of this trial was to examine and compare efficacy of empagliflozin in treatment of ureteric stones in type 2 diabetes patients with tamsulosin.
Methods
Between July 2018 and March 2020, 111 diabetic patients coming to urology outpatient clinics with a single 5–10 mm lower ureteral stone were randomly assigned to two groups: Empagliflozin group (Group A, n=54): Patients got an oral dose of 10 mg of empagliflozin once daily, and Tamsulosin group (Group B, n=57): Patients received tamsulosin 0.4 mg once daily but no SGLT2 inhibitor. The spontaneous passing stones, time required for expulsion, and unfavorable effects were assessed.
Results
There were no significant variations in baseline characteristics between the two groups of patients. In groups A and B, stone expulsion was reported in 75.9% and 77.1% respectively. In group A, the average time to expulsion was 11±4 days, while in group B, it was 13±6 days. The rate of spontaneous stone passage was insignificantly greater in group B, although the stone expulsion time was insignificantly shorter in group A than in group B. The unfavorable effects identified in both groups were comparable in severity and mildness.
Conclusions
In comparison to 0.4 mg tamsulosin, empagliflozin is a safe and efficient medical expulsive therapy for solitary lower ureteral stones < 10 mm in type 2 diabetes individuals. |
| format | Article |
| id | doaj-art-0cda85a0661a48fb9d6d9b605e63916c |
| institution | Kabale University |
| issn | 1687-1693 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Al-Azhar Assiut Medical Journal |
| spelling | doaj-art-0cda85a0661a48fb9d6d9b605e63916c2025-01-17T15:45:05ZengWolters Kluwer Medknow PublicationsAl-Azhar Assiut Medical Journal1687-16932024-01-01221313710.4103/azmj.azmj_53_23Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic PatientsAlsayed S. AbdelazizMohab AS. AbdalazizMostafa M. EbraheemAli A. RaheemAyman M. GhoneemBackground and aim Currently, a new oral diabetes medication comprises inhibition of the sodium-glucose co-transporter 2 (SGLT2), resulting in glycosuria, which may have a dislodging impact on stone ureter. The purpose of this trial was to examine and compare efficacy of empagliflozin in treatment of ureteric stones in type 2 diabetes patients with tamsulosin. Methods Between July 2018 and March 2020, 111 diabetic patients coming to urology outpatient clinics with a single 5–10 mm lower ureteral stone were randomly assigned to two groups: Empagliflozin group (Group A, n=54): Patients got an oral dose of 10 mg of empagliflozin once daily, and Tamsulosin group (Group B, n=57): Patients received tamsulosin 0.4 mg once daily but no SGLT2 inhibitor. The spontaneous passing stones, time required for expulsion, and unfavorable effects were assessed. Results There were no significant variations in baseline characteristics between the two groups of patients. In groups A and B, stone expulsion was reported in 75.9% and 77.1% respectively. In group A, the average time to expulsion was 11±4 days, while in group B, it was 13±6 days. The rate of spontaneous stone passage was insignificantly greater in group B, although the stone expulsion time was insignificantly shorter in group A than in group B. The unfavorable effects identified in both groups were comparable in severity and mildness. Conclusions In comparison to 0.4 mg tamsulosin, empagliflozin is a safe and efficient medical expulsive therapy for solitary lower ureteral stones < 10 mm in type 2 diabetes individuals.https://journals.lww.com/10.4103/azmj.azmj_53_23empagliflozintamsulosindiabetesglucoseureteral stone |
| spellingShingle | Alsayed S. Abdelaziz Mohab AS. Abdalaziz Mostafa M. Ebraheem Ali A. Raheem Ayman M. Ghoneem Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients Al-Azhar Assiut Medical Journal empagliflozin tamsulosin diabetes glucose ureteral stone |
| title | Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients |
| title_full | Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients |
| title_fullStr | Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients |
| title_full_unstemmed | Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients |
| title_short | Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients |
| title_sort | preliminary study expulsive effect of empagliflozin on small lower ureteric stones in type ii diabetic patients |
| topic | empagliflozin tamsulosin diabetes glucose ureteral stone |
| url | https://journals.lww.com/10.4103/azmj.azmj_53_23 |
| work_keys_str_mv | AT alsayedsabdelaziz preliminarystudyexpulsiveeffectofempagliflozinonsmallloweruretericstonesintypeiidiabeticpatients AT mohabasabdalaziz preliminarystudyexpulsiveeffectofempagliflozinonsmallloweruretericstonesintypeiidiabeticpatients AT mostafamebraheem preliminarystudyexpulsiveeffectofempagliflozinonsmallloweruretericstonesintypeiidiabeticpatients AT aliaraheem preliminarystudyexpulsiveeffectofempagliflozinonsmallloweruretericstonesintypeiidiabeticpatients AT aymanmghoneem preliminarystudyexpulsiveeffectofempagliflozinonsmallloweruretericstonesintypeiidiabeticpatients |